Neurogene
NGNE
35 hedge funds and large institutions have $179M invested in Neurogene in 2023 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 7 reducing their positions, and 10 closing their positions.
11,122% more capital inflows, than outflows
Capital inflows: $120M | Capital outflows: $1.07M
40% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 10
30.6% more ownership
Funds ownership: 41.42% → 72.03% (+31%)
29% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 7
13% more funds holding
Funds holding: 31 → 35 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EcoR1 Capital
San Francisco,
California
|
+$18.2M |
| 2 |
Samsara BioCapital
Palo Alto,
California
|
+$18.2M |
| 3 |
Great Point Partners
Greenwich,
Connecticut
|
+$14.2M |
| 4 |
Janus Henderson Group
London,
|
+$12.1M |
| 5 |
Redmile Group
San Francisco,
California
|
+$11.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$149K |
| 2 |
Two Sigma Investments
New York
|
-$135K |
| 3 |
Two Sigma Advisers
New York
|
-$134K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$118K |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$108K |
NGNE Hedge Fund Activity: Q4 2023 in Review
35 of the 6,877 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q4 2023, worth a combined $179M — up 1,141% from $14.4M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new NGNE positions and 10 closed out — a net gain of 4 holders — while 9 added to existing stakes and 7 trimmed.
The largest buyer was EcoR1 Capital, opening a new position worth an estimated $18.2M. The largest seller was Millennium Management, exiting entirely with an estimated $149K sold.
- 35 institutional investors held Neurogene (NGNE) as of Q4 2023, up from 31 in Q3 2023.
- Funds reported $179M of Neurogene stock for Q4 2023, up 1,141% quarter-over-quarter.
- 14 funds opened new Neurogene positions in Q4 2023 and 10 closed out, a net change of +4 holders.
- The largest Neurogene buyer in Q4 2023 was EcoR1 Capital, an estimated $18.2M added.
- The largest Neurogene seller in Q4 2023 was Millennium Management, an estimated $149K sold.
Based on aggregated 13F filings for Q4 2023.